Weiner, L.M.; Dhodapkar, M.V.; Ferrone, S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373, 1033-1040.Zarnani A-H, Bozorgmehr M, Shabani M, Barzegar-Yarmohammadi L, Ghaemimanesh F, Jeddi-Tehrani M. Monoclonal Antibodies for Cancer Immunotherapy. In: Cancer Immunology. ...
Weiner, L., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy.Nat Rev Immunol10, 317–327 (2010). https://doi.org/10.1038/nri2744 Download citation Issue DateMay 2010 DOIhttps://doi.org/10.1038/nri2744 ...
Monoclonal antibodies (mAbs) that regulate the immune response are now being clinically evaluated as anticancer agents. This Review discusses their progress to date and the possibilities for combining these antibodies with other cancer treatments. Increa
Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by ...
The future of therapeutic monoclonal antibodies As our understanding of the molecular mechanisms underlying disease grows, opportunities for the development of new mAb-based drugs increase. In the last decade the focus has been on producing mAbs forcancer immunotherapy, inflammatory disease...
However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results. 展开 关键词:...
a trimeric molecule by the association of the collagenous domains of three identical polypeptide chains. Due to its expression in tumor infiltrating macrophages, and its role in inhibiting immune responses within tumor environment, MARCO has been indicated as a potential target for cancer immunotherapy....
HDAC inhibition potentiates immunotherapy in triple negative breast cancer. "Published figure using CD4 monoclonal antibody (Product # 48-0047-42) in Flow Cytometry" 4.Scientific reports CIB1 and CIB2 are HIV-1 helper factors involved in viral entry. ...
Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A...
Our testing indicates that PerCP-eFluor® 710 conjugated antibodies are stable when stained samples are exposed to freshly prepared 2% formaldehyde overnight at 4°C, but please evaluate for alternative fixation protocols. Excitation: 488 nm; Emission: 710 nm; Laser: Blue Laser. ...